All In Biotech

Drug Trial Radar · NCT05761574

A Study of an Acetaminophen/Naproxen Sodium Fixed Combination, Acetaminophen and Naproxen Sodium in Postoperative Dental Pain

A Full-Factorial, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Dose Efficacy and Safety Study of an Acetaminophen/Naproxen Sodium Fixed Combination, Acetaminophen, and Naproxen Sodium in Postoperative Dental Pain

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 447 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

447

Actual

Start

May 22, 2023

Primary completion

May 17, 2024

Study completion May 30, 2024

Sponsor

Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Mar 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate how well a fixed combination of acetaminophen/naproxen sodium relieves postoperative dental pain compared with acetaminophen, naproxen sodium and placebo.

Conditions

  • Pain

Interventions

  • Acetaminophen/Naproxen Sodium Fixed CombinationDrug

    Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.

  • Naproxen SodiumDrug

    Naproxen Sodium will be administered orally.

  • AcetaminophenDrug

    Acetaminophen will be administered orally.

  • PlaceboDrug

    Placebo will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time-weighted Sum of Pain Intensity Difference From 0 to 12 Hours After Dosing (SPID 0-12)Time frame: Baseline (0 hour) up to 12 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • JBR Clinical Research LLC

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.